Nuwellis, Inc. (NUWE), a medical-device company focused on ultrafiltration therapy, has filed an amended registration statement (S-1/A) with the SEC covering approximately 39,671,056 shares of common stock — a figure that dwarfs the company's roughly 2.6 million currently outstanding shares by a factor of more than 15.

The filing outlines a reasonable best-efforts offering with no minimum raise requirement, priced at $0.76 per share. Because the deal carries no minimum, there is no assurance of any particular amount of capital being raised, while the structural mechanisms embedded in the offering could substantially reshape the company's capitalization.

Warrant Architecture and Reset Mechanics

Each share sold in the offering comes with 4× warrant coverage, split across two series. Series C warrants provide 3-to-1 coverage, while Series D warrants add another 1-to-1 layer. Critically, both series include a reverse-split-triggered price reset provision, meaning the exercise price adjusts downward if the company executes a reverse stock split — a step that is currently pending stockholder approval.

The Series D warrants also include a zero-cash-exercise feature, allowing holders to convert warrants into shares without any additional capital outlay. The offering further includes pre-funded warrants priced at $0.0001, which function as near-equivalent common shares and are typically used to allow investors to stay below beneficial-ownership thresholds while maintaining full economic exposure.

Existing Warrant Repricing and Full-Ratchet Preferred

Beyond the new issuance, the filing discloses a concurrent repricing of approximately 3.28 million previously outstanding warrants down to the $0.76 offering price. This repricing broadens the potential dilution pool by incentivizing exercise of instruments that may have been priced well above current market levels.

Additionally, Nuwellis has outstanding Series F preferred stock that carries full-ratchet anti-dilution protection. Under full-ratchet provisions, any equity issuance at a price below the preferred stock's conversion price automatically resets that conversion price to the new, lower level — increasing the number of common shares into which the preferred can convert, regardless of the size of the triggering issuance.

Going-Concern Context

The filing notes going-concern language in the company's financial statements, indicating substantial doubt about its ability to continue operating. The combination of a sub-dollar offering price, near-zero-cost conversion features, variable pricing mechanics, and a registration covering more than 15 times the current float creates a capital structure in which the effective share count could expand significantly depending on how and when the various instruments are exercised or converted.

Retail shareholders tracking NUWE should note the layered nature of the potential dilution: it does not stem from a single mechanism but rather from the interaction of multiple overlapping provisions — warrant coverage ratios, reset triggers, cashless exercise rights, full-ratchet preferred conversion, and the repricing of legacy warrants — all contingent on the outcome of a pending reverse stock split vote.

The filing is publicly available on the SEC's EDGAR database.